SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions

SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions

Naser Eddin Gharaibeh, Marie-Noel Rahhal, Leili Rahimi, Faramarz Ismail-BeigiDepartment of Medicine, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, OH, 44106, USAAbstract: Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as a major expan...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gharaibeh NE, Rahhal MN, Rahimi L, Ismail-Beigi F
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
Fatty liver
insulin resistance
beta-oxidation
liver biopsy
de novo lipid synthesis
Specialties of internal medicine
RC581-951
Acceso en línea:https://doaj.org/article/22d788df11744ba6b7f59009abbb9ec9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares